GLP‐1 receptor agonist liraglutide alleviates kidney injury by regulating nuclear translocation of NRF2 in diabetic nephropathy

Tingting Lin,Yuze Zhang,Qifeng Wei,Zugui Huang
DOI: https://doi.org/10.1111/1440-1681.70003
2024-10-31
Clinical and Experimental Pharmacology and Physiology
Abstract:Abstract Diabetic nephropathy (DN) is a severe renal disorder that arises as a complication of diabetes. Liraglutide, an analogue of a glucagon‐like peptide 1 (GLP‐1) receptor agonist, has been shown to decrease diabetes‐caused renal damage. Nevertheless, the complete understanding of the roles and mechanism remains unclear. In our study, diabetic rat models were created through a single intraperitoneal injection of streptozotocin (STZ). The level of fasting blood glucose, 24‐h urine protein, serum creatinine (Scr) and blood urea nitrogen (BUN) were assessed. Periodic acid‐Schiff (PAS) staining was applied to examine the pathological changes in renal tissues. Reactive oxygen species (ROS) formation was measured via dichloro‐dihydro‐fluorescein diacetate (DCFH‐DA) probes. Western blot was conducted to examine the levels of oxidative stress‐related and extracellular matrix (ECM)‐associated proteins. The nuclear translocation of NRF2 was investigated through immunofluorescence and Western blot assays. We demonstrated that liraglutide attenuated DN‐induced oxidative stress and ECM deposition in vitro and in vivo. Liraglutide exerted a reno‐protective effect by promoting nuclear translocation of NRF2 in mesangial cells. ML385, an NRF2 inhibitor, counteracted the beneficial impact of liraglutide.
pharmacology & pharmacy,physiology
What problem does this paper attempt to address?